• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Home
  • About Us
  • Blog
  • Subscribe to the Journal
  • Contact Us
Sleep Diagnosis and Therapy

Sleep Diagnosis and Therapy

Official Publication of the American Sleep and Breathing Academy

FDA Social Media Rules Impractical, say Pharma Groups

September 26, 2014 by admin

 

Should pharma companies be held legally responsible for social media content on their products posted by third parties or on third-party websites? To what extent would it discourage them from interacting with consumers via social media? Would this then deny consumers correct information about their products?

 

Pharmaceutical groups have raised unanimous concerns on FDA’s draft social media guidance released in June 2014. (see http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM401087.pdf ). They fear it holds them accountable for misinformation about their products posted online by third parties over whom they have little or no control.

 

The Pharmaceutical Research and Manufacturers of America urged the FDA to limit the manufacturers’ accountability for online content to the extent it was developed or posted by or on behalf of the manufacturer. The also called for clear guidelines to correct misleading third-party information regarding their products’ off-label uses (including permission to link to any FDA-compliant site while doing so).

 

The Biotechnology Industry Organization pointed out the lack of clarity in FDA’s interpretation of the influence or control pharma companies were expected to have. It called for FDA to provide greater flexibility to manufacturers to correct misinformation on social media, including “broad protection under the First Amendment”.

 

The Medical Information Working Group asserted that pinning such responsibility on manufacturers would be “impermissibly broad” and beyond FDA’s statutory authority. They termed this impracticable in today’s social media context, where interactive communication and user-generated content are unpredictable.

 

Source: The Hill

Filed Under: Articles, Blog

Primary Sidebar

More to See

Snoring, American Sleep and Breathing Academy and the NY Times

August 23, 2022 By admin

Jazz Pharma Presents 17 New Posters for SLEEP 2022

June 6, 2022 By admin

Tags

apnea CPAP Health Home Sleep Home Sleep Testing insomnia narcolepsy obstructive sleep apnea Sleep sleep apnea sleep apnea symptoms sleep apnea syndrome sleep apnea treatment sleep appliances sleep buisness Sleep Business sleep center Sleep Centers sleep community sleep diagnosis sleep diagnostic sleep diagnostics sleep disease sleep disorder sleep disorder center sleep disordered breathing sleep disorders sleep heart health sleep industry sleeping Sleep Lab sleep labs sleep management sleep medicine sleep monitor sleep physicians sleep problems sleep studies sleep study sleep technologist sleep test sleep testing Technology therapy Treatment

Footer

About SleepDT

SleepDT Sleep Diagnosis and Therapy is a clinical Journal for allied Sleep Professionals, Neurologists, Psychiatrists, Pulmonologists, Primary Care Physicians, and other medical specialists. We also advocate on behalf of patient care in the field of Sleep Medicine

Recent

  • SUPPORT AND PROMOTE DENTAL SLEEP MEDICINE IN 2023!
  • Snoring, American Sleep and Breathing Academy and the NY Times
  • Jazz Pharma Presents 17 New Posters for SLEEP 2022
  • AJMC Hypes SLEEP 2022
  • Avadel Pharmaceuticals’ Stock Falls

NAVIGATION

  • Home
  • About Us
  • Blog
  • Subscribe to the Journal
  • Contact Us

Copyright © 2023 · Sleep Diagnosis and Therapy